AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$MEDP

Troendle August J. sold $6.7M of MEDP

Troendle August J. (President & CEO) sold 10,880 shares of Medpace Holdings, Inc. (MEDP) at $620.40 ($6.75M total) on 2026-09-17.

Original reporting
SEC EDGAR · Troendle August J.
Published Sep 21, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MEDP
Bearish
medium confidence
Mentioned
$MEDP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDPBearishLow
01

Why it matters

The CEO's sale reduces insider ownership and may affect investor perception.

02

Market read

Insider sell of $6.7M by Medpace's CEO could pressure the stock in the short term.

03

What to watch

The transaction was not pre‑arranged under a 10b5‑1 plan, suggesting discretionary timing.

Relevance 6/10Novelty 7/10Timing: same‑day filing

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$MEDPBearishMedium confidence
Context

CEO Troendle August J. sold 10,880 shares for $6.75M, reducing his stake to 504,273 shares.

Expected impact

Potential short‑term pressure on MEDP stock, possible 2‑4% dip.

Evidence & confidence

Insider sales by top executives often precede price weakness, especially when the sale size exceeds $5M.

Market effects

Sector

May raise questions about Medpace's pipeline and cash flow, affecting other clinical‑research firms.

Regional

Limited to U.S. biotech sector, no broader regional effect.

Global

Low; only relevant to investors tracking MEDP and similar CRO stocks.

Counterpoint

What could challenge this read

The sale could be a routine diversification move, not a bearish signal.

Key entities

  • Company
    Medpace Holdings, Inc.

    Clinical research organization listed on NASDAQ.

  • Executive
    Troendle August J.

    President & CEO of Medpace.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MEDP insider trading history →

Related articles

OCT 23
$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

finance.yahoo.com2 min
OCT 22
$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

tradingview.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

finance.yahoo.com2 min
OCT 22
$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

finance.yahoo.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.

investing.com2 min